Abstract
Serotonin (5-hydroxytryptamine, 5-HT) is a critical local regulator of epithelial homeostasis in the breast and exerts its actions through a number of receptors. Dysregulation of serotonin signaling is reported to contribute to breast cancer pathophysiology by enhancing cell proliferation and promoting resistance to apoptosis. Preliminary analyses indicated that the potent 5-HT1B/1D serotonin receptor agonist 5-nonyloxytryptamine (5-NT), a triptan-like molecule, induced cell death in breast cancer cell lines. Thus, we synthesized a series of novel alkyloxytryptamine analogues, several of which decreased the viability of various human cancer cell lines. Proteomic and metabolomic analyses showed that compounds 6 and 10 induced apoptosis and interfered with signaling pathways that regulate protein translation and survival, such as the Akt/mTOR pathway, in triple-negative breast cancer cells.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1072-1076 |
| Number of pages | 5 |
| Journal | ACS Medicinal Chemistry Letters |
| Volume | 8 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 12 2017 |
Keywords
- Breast cancer
- serotonin receptor
- tryptamine
ASJC Scopus subject areas
- Biochemistry
- Drug Discovery
- Organic Chemistry
Fingerprint
Dive into the research topics of 'Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS